TG Therapeutics, Inc. (TGTX) — Fair Value Analysis
Base-case fair value (P50): $74.24 · Current price: $54.40 · Verdict: Undervalued
The Verdict on TGTX
TG Therapeutics (TGTX) appears undervalued based on our latest Monte Carlo simulations. The median fair value (P50) for TGTX is calculated at $74.24, standing notably above its current market price of $54.40. This implies a significant +36.5% potential, suggesting the market may not be fully appreciating TGTX's underlying intrinsic value through various forward-looking scenarios. The comprehensive analysis indicates a strong positive bias for the stock's valuation, despite the company operating in a sector currently designated as n/a in our dataset.
How TGTX stacks up against peers
While TG Therapeutics' operational and financial health is categorized as an average quality tier compared to its sector peers, this assessment does not diminish the compelling undervaluation identified. The Monte Carlo analysis considers thousands of potential future market conditions and company performance metrics, yielding a median fair value of $74.24 that significantly exceeds the current trading price of $54.40. This indicates that even with its average quality standing, TGTX's current market capitalization at $54.40 is considered modest relative to its fundamental prospects.
What this means for investors
The substantial +36.5% between TGTX's current price of $54.40 and its median fair value of $74.24 presents a notable opportunity for investors. While all investments carry risk, including potential downside scenarios, the simulation-derived fair value suggests a strong favorable outlook. Understanding the full spectrum of potential outcomes, from bull case scenarios to more conservative projections, is crucial for informed decision-making. To gain deeper insight into these varied outcomes and track TGTX's fair value changes, investors can leverage FairCurve. Sign up for FairCurve to see the full bear/bull distribution and track TGTX's fair value as new fundamentals are released.
Frequently Asked Questions
Is TGTX overvalued or undervalued right now?
Based on Monte Carlo simulations, TG Therapeutics (TGTX) is currently considered undervalued. Our median fair value estimate (P50) is $74.24, significantly above the current price of $54.40.
What is the bear case and bull case for TGTX?
The full Monte Carlo distribution, including specific bear (P10) and bull (P90) price targets, as well as the probability of achieving upside, is available with a free FairCurve account. We do not provide specific dollar values for these scenarios publicly.
How does FairCurve calculate TGTX's fair value?
FairCurve calculates TGTX's fair value using Monte Carlo simulation, running thousands of forward-looking scenarios to determine a robust median fair value estimate. This process integrates various financial models and market data points.
How can I track TGTX's fair value as it changes?
You can add TGTX to a free FairCurve watchlist to receive daily fair-value updates and instant re-valuation whenever new earnings or significant fundamental data are released.